Marvix AI

What is Marvix AI and who sells it?

Marvix AI, Inc. is a Boston, Massachusetts company, according to its PitchBook profile. PitchBook dates the founding to 2024, while Tracxn lists incorporation on October 23, 2023. Shwetank Verma and Rashie Jain (CEO) are named as founders. Tracxn puts total funding at $2.8M, seed stage, privately held. Headcount figures differ by source: PitchBook lists 21 employees, Crunchbase lists 1-10 or 11-50. No acquisition or ownership change is listed.

Its homepage headline reads "Ambient AI Assistant for Specialty Care". The pitch rests on disease-specific templates, notes "that read like Yours", and AI summaries drawn from prior notes, imaging, labs and discharge documents. Platforms listed are iPhone, iPad, web, Zoom and Apple Watch.

What does Marvix do well?

The product list is broad for a company this size. According to the Marvix homepage and pricing page, it covers four jobs beyond the transcript.

The coder suggests ICD-10-CM and CPT E/M codes with a medical decision-making rationale, plus modifiers and add-on codes such as G2211. It also lists Australian code sets (ICD-10-AM, ACHI and MBS numbers), which matters for practices outside the US.

For pre-charting, it can merge patient questionnaires and a clinician's pre-charting dictation into one note, show MIPS prompts, and pull the appointment list from the EHR or practice management system.

For the patient profile, the vendor describes a unified summary from historical EHR notes, key lab progression and a chronic-condition summary aimed at HCC and RAF capture.

Letters are listed too: after-visit summaries, referral letters, and school, work-accommodation and return-to-work letters.

Specialty fit is the main pitch. Marvix lists templates for 135 specialties and gives neurology and oncology their own landing pages. For a neurologist seeing new patients with long histories, a note that pulls in prior imaging and lab trends is more relevant than a generic SOAP template. All of this is the vendor's description and none of it is verified.

The pricing page also lists optional add-ons: Ask Marvix (a chat assistant), Marvix Live (dictation anywhere), AI Summaries and a view-only license for a medical assistant. The homepage mentions AI-assisted differential diagnosis, dynamic macros for the physical exam and imaging summaries as well. A clinician who wants a scribe and nothing else may find the surface area larger than needed.

Pricing is also a point in its favor: the numbers are published, from $95 per provider per month.

Where does it fall short?

The independent-review results are Marvix's own blog posts, including one that ranks Marvix first for neurology. Testimonials from staff at Dent Neurologic Institute appear on the vendor's recap of NeuroNet 2026. They are curated by Marvix.

The homepage promises "Save 2 Hrs / day", "See 15% more patients" and "Earn up to $80k more per doctor/yr". No methodology is shown for any of them.

Marvix's blog states HIPAA and SOC 2 Type 2 compliance, encryption at rest and in transit, and no training on patient data. No auditor report or trust-center page is listed, so the claims are self-declared. HITRUST is not stated. FDA status is not stated. A Business Associate Agreement is not mentioned, and a practice should ask for one in writing before any recording of a patient.

The pricing page says Marvix "Integrates with Most EHRs" and names Athena, eClinicalWorks and AdvancedMD for full integration. Epic and Oracle (Cerner) are not named. Integration is also tier-gated: Collective and Enterprise list EHR integration with a stated zero integration fee, while Basic and Practice show "No integration".

What does Marvix cost?

The Basic plan is $95 per provider per month on the yearly tab ($115 on the monthly tab), as of October 2026, with 75 recording hours per month. Higher tiers run to $200 on the yearly tab and $250 monthly, and overage is $3 per hour. The page does not say whether the yearly figure is billed as one annual payment.

How does Marvix compare?

Marvix's closest comparisons are with Abridge, Freed and Nabla, and the only head-to-head content is Marvix's own: its blog has pages on Abridge alternatives and on Freed versus Nabla. Both are marketing documents.

The verifiable comparison is thin. Marvix competes on a published price and specialty templates, and no like-for-like accuracy or integration data exists against Abridge, Freed or Nabla. If a practice's EHR is Epic, the missing Epic statement on Marvix's pages rules it out until the vendor says otherwise in writing.

Against Freed and Nabla, Marvix's stated difference is coding and pre-charting bundled into the tiers. Whether that bundling saves a coder's time has no data behind it.

What does the evidence say?

No peer-reviewed study validates Marvix, and no accuracy study, time-saving study or error-rate comparison is listed. No clinician comments on Reddit, G2 or KLAS are listed.

For a buyer, the practical answer is to treat the trial as the evidence. Thirty days with two or three of your own visit types, edited notes compared against what you would have dictated, is the only validation available today.

Who is Marvix for?

A solo neurologist or a three-physician oncology group on Athena, eClinicalWorks or AdvancedMD, paying out of practice funds, and open to piloting an unproven vendor at $95 to $150 per provider per month. The homepage lists a one-month free trial. The 75-hour Basic cap works out to about 3.6 hours of recording per working day across 21 working days (75 divided by 21), and overage costs $3 per hour.

It is a poor fit for a hospital-employed physician whose organization standardizes on Epic, for a group that needs a SOC 2 report in hand before procurement, and for anyone buying on the strength of the homepage ROI numbers.

The verdict

Marvix is a plausible, inexpensive specialty scribe with no independent evidence behind it yet. Pilot it if the price and the neurology or oncology templates fit. Do not sign an annual commitment before the trial confirms your EHR connects and the vendor supplies a BAA and its audit report.